SCHEMBL3402019

SCHEMBL3402019

CC1(C)CCC2(CCCC(COc3ccc(CCC(=O)O)cc3)C2)CC1

nearest known ligand 0.45

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 12/20 0.45
LMNA P02545 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
ITGB3 P05106 1/20 0.43
ITGA2B P08514 1/20 0.43
FFAR4 Q5NUL3 4/20 0.42
THRA P10827 1/20 0.41
THRB P10828 1/20 0.41
F2 P00734 1/20 0.40
CYP26A1 O43174 1/20 0.40
CYP26B1 Q9NR63 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3399524 0.91 ITGB3 (0.46) FFAR1LMNAL3MBTL1ITGB3ITGA2B
SCHEMBL3400701 0.91 ITGB3 (0.46) FFAR1LMNAL3MBTL1ITGB3ITGA2B
SCHEMBL3402949 0.90 FFAR1 (0.44) FFAR1LMNAL3MBTL1ITGB3ITGA2B
SCHEMBL3397445 0.86 ITGB3 (0.46) FFAR1LMNAL3MBTL1ITGB3ITGA2B
SCHEMBL3395430 0.86 ITGB3 (0.46) FFAR1LMNAL3MBTL1ITGB3ITGA2B
SCHEMBL3402227 0.85 FFAR1 (0.45) FFAR1LMNAL3MBTL1ITGB3ITGA2B
SCHEMBL3399183 0.83 LMNA (0.45) FFAR1LMNAL3MBTL1ITGB3ITGA2B
SCHEMBL13338066 0.81 ADAM17 (0.46) FFAR1
SCHEMBL3403396 0.81 FFAR1 (0.43) FFAR1LMNAL3MBTL1ITGB3ITGA2B
SCHEMBL3397529 0.80 FFAR1 (0.45) FFAR1LMNAL3MBTL1ITGB3ITGA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2684861-A2 Spiro compounds and pharmaceutical use thereof Japan Tobacco Inc. (JP) 2014-01-15 EP disclosed
US-8299296-B2 Spiro compounds and pharmaceutical use thereof JAPAN TOBACCO INC. (JP) 2012-10-30 US disclosed
US-8299296-B2 Spiro compounds and pharmaceutical use thereof JAPAN TOBACCO INC. (JP) 2012-10-30 US disclosed
EP-2508503-A1 Spiro compounds and pharmaceutical use thereof Japan Tobacco, Inc. (JP) 2012-10-10 EP disclosed
EP-2202216-B1 SPIRO-RING COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES JAPAN TOBACCO INC (JP) 2012-06-27 EP disclosed
EP-2202216-B1 SPIRO-RING COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES JAPAN TOBACCO INC (JP) 2012-06-27 EP disclosed
EP-2202216-A1 SPIRO-RING COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES Japan Tobacco Inc. (JP) 2010-06-30 EP disclosed
US-20090170908-A1 SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC. (JP) 2009-07-02 US disclosed
US-20090170908-A1 SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC. (JP) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170908-A1 SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF REN, PKD1, PKD2 FFAR1 2207/4885LMNA 1204/4885L3MBTL1 4874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.